The long-sought mouse cholinergic toxin has been found! The mouse cholinergic immunotoxin (Cat. #IT-16) is being released for sale at the Society for Neuroscience meeting in New Orleans, November 4-9, 2000! For years ATS has received requests for a molecule that would eliminate cholinergic neurons in the basal forebrain of mice in a manner that […]
Targeting Tools: Mouse-Specific p75 Immunotoxin Read More »
Q: What is a second immunotoxin? A: ATS’s second immunotoxins are conjugations of a secondary antibody (as of December 2000, either goat anti-mouse IgG or goat anti-rabbit IgG) to the ribosome-inactivating protein, saporin. Q: How does a second immunotoxin target? A: The second immunotoxin uses the secondary antibody to “piggyback” onto your primary antibody in
Second Immunotoxins Read More »
Gu Z, Wortwein G, Yu J, Perez-Polo JR (2000) Model for aging in the basal forebrain cholinergic system. Antiox Redox Signal 2(3):437-447. doi: 10.1089/15230860050192215 Summary: A wide range of evidence indicates that cholinergic neurons play a role in memory and learning. Loss of these neurons is seen both in aged subjects and Alzheimer’s Disease patients.
Model for aging in the basal forebrain cholinergic system. Read More »
Lappi DA, Wiley RG (2000) Entering through the doors of perception: characterization of a highly selective Substance P receptor-targeted toxin. Neuropeptides 34(5):323-328. doi: 10.1054/npep.2000.0827 Related Products: Dermorphin-SAP / MOR-SAP (Cat. #IT-12)
Beach T (2000) Featured Article: CBF lesioning in rabbits. Targeting Trends 1(1) Related Products: ME20.4-SAP (Cat. #IT-15) Read the featured article in Targeting Trends. See Also: Beach TG et al. Cholinergic deafferentation of the rabbit cortex: a new animal model of Abeta deposition. Neurosci Lett 283:9-12, 2000.
Featured Article: CBF lesioning in rabbits Read More »
In April of this year ATS applied for funding from National Institute for Mental Health (NIMH) for the toxicology studies of Substance P-Saporin (SP-SAP). This $674,000 supplement to a previous NIMH Small Business Innovative Research grant will cover one of the FDA-required safety and toxicology studies and will bring us closer to clinical trials in
Chronic Pain Therapeutic Read More »
Advanced Targeting Systems (ATS) has just been awarded a $100,000 research grant from the National Institute on Drug Abuse (NIDA). This Phase I SBIR (Small Business Innovation Research) grant proposes to develop a research reagent to study the function of the neuropeptide, galanin. This will be an important tool for scientists to use in the
NIDA funds ATS research on Galanin Read More »
Contributed by Dr. Thomas Beach, Sun Health Research Institute, Sun City, AZ Our hypothesis, developed through our own human and animal studies1-6 and the cell culture work of others (beginning with Nitsch7), is that the normal, age-related loss of cortical cholinergic innervation leads to Aβ deposition and Alzheimer’s disease. To test this hypothesis, we have been
Cover Article: CBF Lesioning in Rabbits Read More »
Silveira DC, Holmes GL, Schachter SC, Geula C, Schomer DL (2000) Increased susceptibility to generalized seizures after immunolesions of the basal forebrain cholinergic neurons in rats. Brain Res 878:223-227. doi: 10.1016/s0006-8993(00)02703-7 Usage: 192-SAP (Cat. #IT-01), 4 µg intracerebroventricular injection Related Products: 192-IgG-SAP (Cat. #IT-01)
Taylor BK, Roderick RE, Basbaum AI (2000) Brainstem noradrenergic control of nociception is abnormal in the spontaneously hypertensive rat. Neurosci Lett 291:139-142. doi: 10.1016/s0304-3940(00)01389-6 Usage: anti-DBH-SAP (Cat. #IT-03), 5 µg Related Products: Anti-DBH-SAP (Cat. #IT-03)